Implied Podcast

Carvana just hit a massive speed bump, crashing 20% in a single day after a scathing report from Gotham City Research. The allegations are explosive: a $1 billion hole in the books and claims that Carvana’s "record profits" are actually a mirage propped up by secret, "incestuous" deals with the CEO’s family businesses. In this episode of Implied, we dig into the claims of artificial gains, the 40x debt-to-earnings ratio looming over their partners, and whether Carvana is a logistics marvel or a financial thriller waiting for a crash. Is this the ultimate buying opportunity, or is the "family business" finally catching up to them? Tune in to go behind the numbers.

Figma just hit a painful milestone: its stock is hovering around $29, officially sliding below its $33 IPO price. Despite crossing the massive $1 billion annual recurring revenue mark with elite 90% gross margins, Wall Street is hit with a "post-IPO hangover." In this episode, we dive into why the market is panicking over a $1 billion GAAP loss fueled by one-time stock comps while ignoring Figma’s $1.6 billion cash pile and zero debt. Is this a "baby with the bathwater" situation caused by lockup expirations, or is Adobe’s AI counter-offensive finally catching up? Tune in to find out if Figma is a high-quality business trapped in a low-quality chart.

Revolution Medicines (RVMD) just saw its stock crater 17% after reports surfaced that Merck has officially pulled the plug on its rumored $30 billion takeover. After weeks of intense M&A hype and a 50% rally, the "takeover premium" is evaporating, leaving investors with a classic case of "selling the lack of news."

In this episode, we break down:

• The Valuation Standoff: Why Merck walked away from the table and why AbbVie isn't coming to the rescue.

• The "Zero Revenue" Reality: How a company burning $1 billion a year maintains a massive $1.9 billion cash cushion.

• The Science vs. The Hype: Why the upcoming Phase 3 data for daraxonrasib might be the only thing that can save the bulls.

Is this a crash to avoid, or a rare, discounted entry into the "holy grail" of oncology? Tune in to find out if the science under the hood is enough to overcome the loss of a mega-merger.

Legend Biotech just slammed into a new 52-week low, plunging 11% after missing sales estimates for its flagship cancer drug, Carvykti. Wall Street’s reaction was brutal—with analysts slashing price targets from $62 to $21—but management is standing firm on its $3 billion forecast. Is this a disastrous sign of stalling demand, or does the crash make Legend a bargain buyout target for Big Pharma? In this episode, we break down the numbers to see if this is a value trap or a golden opportunity in the cell therapy space.

AeroVironment (AVAV) just shed nearly 16% after the U.S. government slammed the brakes with a surprise "Stop Work Order" on its classified BADGER program. Despite explosive 151% revenue growth from the recent BlueHalo acquisition, a messy earnings miss and this sudden Pentagon freeze have investors running for the exits. Is this a sign of deep trouble in their defense contracts, or is the market ignoring a $1.4 billion backlog and a rare buying opportunity? Tune in as we break down whether this drop is a discount or a warning.

AST SpaceMobile just defied gravity, surging over 14% to a fresh all-time high after securing a prime spot on the U.S. Missile Defense Agency’s massive SHIELD program. With a contract ceiling of $151 billion, Wall Street is betting that ASTS is no longer just a cellular play—it’s a critical defense asset. In this episode of Implied, we break down how this "dual-use" validation changes the narrative, why investors are ignoring the dizzying 3,000x sales valuation, and whether AST can actually compete against titans like Lockheed Martin. Is this the start of a new era, or is the stock priced for perfection? Tune in to find out.

Ermenegildo Zegna stock has slid nearly 13% from last week’s highs after Bank of America downgraded the luxury house, slapping a sober $10 price target on the ticker. The core issue? Zegna is trading at a premium 22x earnings—rivaling industry titan LVMH—while its "cool" brand Thom Browne is shrinking and its pivot away from wholesale is dragging down cash flow. In this episode of Implied, we break down why the market is treating this "transition year" like a top-tier luxury play, and whether the "Made in Italy" label justifies the price tag while the engine is still being fixed.

Reddit just shed nearly 10% of its value in a single session, caught in a brutal tug-of-war between Wall Street analysts. While bulls recently slapped a $320 target on the stock for its AI data potential, a stinging new report warns that the core ad business is cracking as small businesses pull back. With a massive 65 P/E ratio "priced for perfection" and executives unloading shares right before the drop, the market is suddenly terrified. In this episode of Implied, we break down the mixed signals and ask: Is this a discount on a future tech giant, or a falling knife you shouldn’t catch?

Trip.com just nose-dived nearly 20% overnight, blindsiding investors with a sudden antitrust investigation from Chinese regulators. It was supposed to be the "safe" bet in Chinese tech, riding high on a post-pandemic travel boom and new visa-free policies—but now, fears of a renewed crackdown are back. In this episode, we break down why the "King of Travel" is under fire, what a potential breakup of its dominance means for the stock, and whether this massive drop is a discount or a value trap.

Dave Inc. (DAVE) just capped off a brutal week, plunging nearly 23% amid Fed controversy and fears of new banking regulations. The twist? The company just refinanced its debt and analysts argue it has zero exposure to the fees driving the market panic. In this episode, we break down the massive disconnect between Dave’s crashing stock price and its booming 63% revenue growth. Is this a "mistaken identity" sell-off creating a rare discount, or is it dangerous to catch a falling knife in this volatile sector? Dive in to see why the facts might contradict the fear.